此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

[未经美国 FDA 批准或许可的设备的试用] (INNOVATE)

2026年11月3日 更新者:BrioHealth Solutions, Inc.

The goal of this study is to evaluate the safety and efficacy of the BrioVAD System by demonstrating non-inferiority to the HeartMate 3 Left Ventricular Assist System when used for the treatment of advanced, refractory, left ventricular heart failure.

研究概览

详细说明

The INNOVATE Trial is a prospective, non-blinded, randomized, controlled, multi-center, non-inferiority study to evaluate the safety and efficacy of the BrioVAD System by demonstrating non-inferiority to the HeartMate 3™ (HM3) LVAS (Abbott) when used for the treatment of advanced, refractory left ventricular heart failure. It is the first clinical study to compare two left ventricular assist devices (LVAD) that belong to the same category of fully magnetically levitated LVAD.

研究类型

介入性

注册 (估计的)

780

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Alabama
      • Birmingham、Alabama、美国、35233
        • University of Alabama at Birmingham Hospital
    • Arkansas
      • Little Rock、Arkansas、美国、72205
        • Baptist Health Medical Center-Little Rock
    • California
      • Los Angeles、California、美国、90048
        • Cedars-Sinai Medical Center
    • Florida
      • Gainsville、Florida、美国、32608
        • UF Health Shands Hospital
      • Orlando、Florida、美国、32803
        • Advent Health
    • Georgia
      • Atlanta、Georgia、美国、30322
        • Emory University
      • Atlanta、Georgia、美国、30309
        • Piedmont Healthcare
    • Illinois
      • Chicago、Illinois、美国、60611
        • Northwestern University
      • Chicago、Illinois、美国、60637
        • University of Chicago
      • Chicago、Illinois、美国、60453
        • Advocate Christ Medical Center
    • Indiana
      • Indianapolis、Indiana、美国、46260
        • Ascension St. Vincent Hospital - Indianapolis
    • Kansas
      • Kansas City、Kansas、美国、66160
        • The University Of Kansas Medical Center
    • Kentucky
      • Lexington、Kentucky、美国、40536
        • University of Kentucky
      • Louisville、Kentucky、美国、40202
        • University of Louisville
    • Maryland
      • Baltimore、Maryland、美国、21201
        • University of Maryland Medical Center
      • Baltimore、Maryland、美国、21287
        • The Johns Hopkins Hospital
    • Massachusetts
      • Boston、Massachusetts、美国、02114
        • Massachusetts General Hospital
      • Boston、Massachusetts、美国、02111
        • Tufts Medical Center
    • Michigan
      • Ann Arbor、Michigan、美国、48109
        • University of Michigan
      • Detriot、Michigan、美国、48202
        • Henry Ford Health
      • Grand Rapids、Michigan、美国、49503
        • Corewell Health Grand Rapids Hospital
    • Minnesota
      • Minneapolis、Minnesota、美国、55455
        • University of Minnesota
      • Minneapolis、Minnesota、美国、55407
        • Abbott Northwestern Hospital
    • Missouri
      • St Louis、Missouri、美国、63110
        • WashU Medicine
    • Nebraska
      • Omaha、Nebraska、美国、68198
        • University of Nebraska Medical Center
    • New Jersey
      • Newark、New Jersey、美国、07112
        • Newark Beth Israel Medical Center
    • New York
      • New York、New York、美国、10065
        • Weill Cornell Medicine
      • New York、New York、美国、10016
        • NYU Langone Health
      • New York、New York、美国、10029
        • Mount Sinai
      • New York、New York、美国、10032
        • Columbia University Irving Medical Center/ New York Presbyterian Hospital
      • The Bronx、New York、美国、10467
        • Montefiore Medical Center
    • North Carolina
      • Durham、North Carolina、美国、27710
        • Duke University
    • Ohio
      • Cincinnati、Ohio、美国、45219
        • The Christ Hospital - Cincinnati
      • Cleveland、Ohio、美国、44195
        • Cleveland Clinic
    • Oregon
      • Portland、Oregon、美国、97239
        • Oregon Health & Science University
    • Pennsylvania
      • Philadelphia、Pennsylvania、美国、19107
        • Thomas Jefferson University Hospital
    • South Carolina
      • Charleston、South Carolina、美国、29425
        • Medical University of South Carolina
    • Tennessee
      • Memphis、Tennessee、美国、38120
        • Baptist - Memphis (Stern)
    • Texas
      • Dallas、Texas、美国、75246
        • Baylor University Medical Center, part of Baylor Scott & White Health
      • Dallas、Texas、美国、75390
        • UT southwestern Medical Center
      • Houston、Texas、美国、77030
        • Houston Methodist Hospital
      • Houston、Texas、美国、77030
        • Memorial Hermann-Texas Medical Center
      • Houston、Texas、美国、77030
        • Texas Heart Institute at Baylor St. Luke's Medical Center
      • Plano、Texas、美国、75093
        • Baylor Scott & White Medical Center - Plano
    • Utah
      • Salt Lake City、Utah、美国、84132
        • University of Utah
    • Virginia
      • Falls Church、Virginia、美国、22042
        • Inova Fairfax Medical Campus
    • Wisconsin
      • Milwaukee、Wisconsin、美国、53215
        • Aurora St. Luke's Medical Center

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 100年 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  1. Patient is ≥ 18 years of age.

  2. Patient has received institutional approval for LVAD implantation.

  3. Patient has a body surface area (BSA) ≥ 1.2 m2.

  4. Patient is classified as NYHA Class IV with advanced heart failure refractory to advanced heart failure management or NYHA Class III with dyspnea upon mild physical activity.

  5. Patient has a left ventricular ejection fraction (LVEF) ≤ 25% or LVEF < 30% on inotropes or temporary MCS.

  6. Patient is inotrope dependent, OR has a cardiac index (CI) ≤ 2.2 liters/min/m2, while not on inotropes, and also meets one of the following criteria:

    1. Is on optimal medical management (OMM), based on current heart failure practice guidelines for at least 45 out of the last 60 days and is failing to respond or is not able to tolerate OMM; or
    2. Has advanced heart failure for at least 14 days and is dependent on an intra-aortic balloon pump (IABP) or temporary mechanical circulatory support device (MCSD) for at least seven days.
  7. Patient has provided voluntary and informed consent.

  8. Females of childbearing age agree to use adequate contraception and have a negative pregnancy test.

Exclusion Criteria:

  1. Patient's heart failure etiology is related to restrictive or constrictive physiology (e.g., nondilated hypertrophic cardiomyopathy, cardiac amyloidosis/senile or other infiltrative disease), complex congenital heart disease (e.g., transposition of the great vessels), uncorrected thyroid disease, and/or pericardial disease.

  2. Patient had a myocardial infarction within seven days of study enrollment.

  3. Patient had cardiothoracic surgery within 30 days of implant with the exception of a procedure to implant temporary MCS: Impella 5.5, Impella CP or TandemHeart.

  4. Patient has physiological conditions or comorbidities which pose high surgical risk or obstacles as determined by the Investigator.

  5. Patient has contraindications to warfarin anticoagulation.

  6. Patient has known hypo- or hypercoagulable state [e.g., disseminated intravascular coagulation (DIC)], or has a positive heparin-induced thrombocytopenia (HIT) assay and positive serotonin release assay or requires use of a non-heparin alternative anticoagulation strategy for cardiopulmonary bypass in the judgement of the Investigator.

  7. Patient is on durable MCS (e.g., LVAD or RVAD).

  8. Planned need for durable or temporary RVAD support concomitant with LVAD implant.

  9. Patient is on any form of pre-implant temporary MCS other than isolated LVAD support with an intra-aortic balloon pump, Impella 5.5, Impella CP, or TandemHeart.

  10. Patient is on any form of pre-implant temporary MCS and has a serum lactate dehydrogenase greater than 2.5 times the upper limits of normal or plasma free hemoglobin > 40 g/dL.

  11. Patient has a history of organ transplantation.

  12. Patient has a mechanical aortic valve that may not be converted to a bioprosthetic valve at the time of VAD implant.

  13. Patient has a platelet count < 50 k/μl.

  14. Patient has a history of confirmed untreated abdominal aortic aneurysm (AAA) > 5 cm in diameter.

  15. Patient has moderate or severe aortic insufficiency that will not be corrected during the VAD implant procedure.

  16. Patient has an uncontrolled systemic infection.

  17. Patient has a positive COVID 19 test within 21 days of study enrollment and at least one high risk feature including need for supplemental oxygen or ferritin >1000 ug/L.

  18. Patient has severe end-organ dysfunction as evidenced by one or more of the following criteria:

    1. Total bilirubin > 3.0 mg/dL or cirrhosis confirmed by liver imaging or hemodynamic assessment with or without biopsy confirmation.
    2. International normalized ratio (INR) ≥ 2.0 or PTT > 2.5 times control that is not related to anticoagulation therapy.
    3. Glomerular filtration rate (GFR) < 30 mL/ min/1.73 m2 or need for renal replacement therapy.
    4. Severe pulmonary arterial hypertension with a pulmonary vascular resistance (PVR) ≥ 8 Wood units that is not acutely reversible with pharmacologic intervention.
    5. Severe chronic obstructive pulmonary disease (COPD) or restrictive lung disease requiring home oxygen or an FEV1/FVC < 0.7 and FEV1 < 40% predicted.
    6. Mechanical ventilation for more than three days present at the time of study enrollment.
    7. Documented history of pulmonary embolism or pulmonary infarct within 60 days of study enrollment.
    8. History of stroke within 90 days of study enrollment or history of stroke with a mRS ≥ 3 at the time of study enrollment.
    9. Symptomatic cerebrovascular disease and/or uncorrected carotid stenosis > 80%.
    10. Significant peripheral vascular disease (PVD) accompanied by pain at rest or extremity ulceration.
    11. Pre-albumin < 15 mg/dL and/or albumin < 2.5 g/dL.
  19. Patient has a non-cardiac comorbidity or illness that would limit survival to less than two years.

  20. Patient has a psychiatric disease or disorder, or irreversible cognitive dysfunction, and/or insufficient social support or a history of non-adherence with medical instructions that is likely to impair study compliance.

  21. Patient is participating in an interventional clinical trial that may impact or confound the results of the INNOVATE Trial.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:BrioVAD System

BrioVAD® Left Ventricular Assist System (BrioVAD® System) by BrioHealth Solutions, Inc.

Implantation of the BrioVAD System to evaluate the safety and efficacy of the BrioVAD System by demonstrating non-inferiority to the HeartMate 3 LVAS when used for the treatment of advanced, refractory, left ventricular heart failure.

有源比较器:HeartMate 3

HeartMate 3 System by Abbott

Implantation of the commercially approved HeartMate 3 LVAS, which is the standard treatment for advanced heart failure.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Short-Term Indication Primary Endpoint
大体时间:6 months

Composite of survival to transplant, recovery or 6 months of LVAD support free of debilitating stroke [modified Rankin Scale (mRS) > 3], or reoperation to replace the pump

6 months
Long-Term Indication Primary Endpoint
大体时间:24 months

Composite of survival to transplant, recovery or 24 months of LVAD support free of debilitating stroke (mRS > 3), or reoperation to replace the pump.

24 months

次要结果测量

结果测量
措施说明
大体时间
Powered Secondary Endpoint
大体时间:24 months

Total number of nights in hospital, skilled nursing facility, or inpatient rehabilitation, inclusive of index hospitalization, through 24 months post VAD implant, heart transplantation, VAD explant or decommission, study withdrawal, or death, whichever occurs first.

24 months
Short-Term Indication Secondary Endpoint
大体时间:6 months

Evaluation of the short-term safety using INTERMACS adverse event (AE) terms and definitions through 6 months post VAD implant, heart transplantation, VAD explant or decommission, study withdrawal, or death, whichever occurs first. Incidences of all AEs and the event rate per patient year of support through 6 months will be reported. Differences in the event rates between the Study Arm and the Concurrent Control Arm will be analyzed. Serious adverse events (SAEs) will be analyzed in a similar manner.

6 months
Long-Term Indication Secondary Endpoint
大体时间:24 months

Evaluation of the long-term safety using INTERMACS AE terms and definitions through 24 months post VAD implant, heart transplantation, VAD explant or decommission, study withdrawal, or death, whichever occurs first. Incidences of all AEs and the event rate per patient year of support through 24 months will be reported. Differences in the event rates between the Study Arm and the Concurrent Control Arm will be analyzed. SAEs will be analyzed in a similar manner

24 months

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2024年10月28日

初级完成 (估计的)

2028年2月1日

研究完成 (估计的)

2028年12月1日

研究注册日期

首次提交

2024年3月7日

首先提交符合 QC 标准的

2024年3月7日

首次发布 (实际的)

2024年3月13日

研究记录更新

最后更新发布 (实际的)

2026年11月5日

上次提交的符合 QC 标准的更新

2026年11月3日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

未定

IPD 计划说明

Protocol and data is company confidential.

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

是的

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅